Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)

0
77
Federal grants application on Grants.Gov

Funding Opportunity ID:308981
Opportunity Number:RFA-CA-18-029
Opportunity Title:Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)
Opportunity Category:Discretionary
Opportunity Category Explanation:
Funding Instrument Type:Cooperative Agreement
Category of Funding Activity:Education
Health
Category Explanation:
CFDA Number(s):93.393
93.399
Eligible Applicants:State governments
Public and State controlled institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility:Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. see the funding announcement for eligibility details
Agency Code:HHS-NIH11
Agency Name:Department of Health and Human Services
National Institutes of Health
Posted Date:Sep 14, 2018
Close Date:Nov 15, 2018
Last Updated Date:Sep 14, 2018
Award Ceiling:$625,000
Award Floor:$0
Estimated Total Program Funding:
Expected Number of Awards:
Description:The purpose of this RFA is to support early clinical trials consortia poised to efficiently evaluate the biologic effects of cancer preventive agents and to determine clinically-relevant correlates in order to advance their development for cancer prevention. The program objectives are: To efficiently design and conduct early phase clinical trials to assess the cancer preventive potential of NCI-sponsored agents of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (microdosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials. To characterize the effects of these agents on the molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlate these effects with clinical endpoints. To develop further scientific insights into the mechanism of cancer prevention by the agent examined and continue to develop novel potential markers as determinants of response.
Version:1





Visit the Official Webpage For More Details on Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)